|
||
| |||||||
|
Atrial Fibrillation - Future Advances in Stroke Prevention The current estimated prevalence of atrial fibrillation (AF) across the seven major markets is 7.65m, estimated to grow at a CAGR of 1.48% to 2011, driven by the ageing population. Current treatment options including anti-arrhythmic drug therapy, devices and procedures are limited, and the high risk of stroke in AF patients identifies this market as an area of significant unmet need. Scope To segment patients by type of AF - recent onset, paroxysmal, persistent and permanent - and to establish the impact of recent guidelines on therapy To assess the current status of the rhythm vs. rate control debate, and the determining factors for each type of treatment strategy To determine the current role of anticoagulants in the treatment of AF and the potential future impact of Exanta in stroke prevention Report Highlights Rhythm control was considered the best strategy in AF, but recent studies have suggested that rate control is equally valid. Datamonitor’s survey reveals an even 50:50 split in the use of these strategies, although failure rates and side-effects are high, up to 40% at first line, demonstrating the unmet need for new anti-arrhythmic agents. Despite the high risk of stroke, estimated at 6% of the AF population per year, only 81% of high risk patients are currently receiving oral anticoagulation for stroke prevention. Datamonitor estimates that the potential market for AstraZeneca’s new oral anticoagulant, Exanta (ximelagatran) at 1.4m patients across the seven major markets. Current usage of cardiac rhythm devices and catheter ablation in AF management is low, with up to 12% of patients receiving these therapies. Barriers to their use include high costs, low eligibility and lack of physician experience. However, in the absence of a cure for AF, they will play an increasing role in ‘hybrid’ strategies. Reasons to Purchase Identify and quantify the sub-populations at each stage of AF and understand their differential treatment and unmet needs Assess the potential for hybrid anti-arrhythmic, cardiac rhythm management devices and catheter ablation therapy strategies Understand the current level of awareness and perception of Exanta, and the likely uptake in both existing and new patients January 2004 Pages: 215 Publisher: Datamonitor Cardiovascular Reports 2004 To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Cardiovascular_Reports_2004.html#a531 |
|
|
